IHC analysis of Cyclin D1, Syk and PLK1 expression in tumor xenografts and image analysis based quantitation of immunostained tissue sections using Visiopharm software showed 54%, 46% and 33% nuclear positivity in ER maleate treated group at 1mg/kg bwt, 21%, 31% and 15% in group at 3mg/kg bwt, 5%, 21% and 2.6% in group receiving combination of carboplatin and ER maleate, 41%, 35% and 19% in carboplatin treatment alone, and 82%, 92% and 77% in control group, respectively (Figure 9I). The gene discussed is PLK1; the disease is neoplasm.